Refine by
Cancer Nsclc Suppliers & Manufacturers
27 companies found
based inDaejeon, SOUTH KOREA
PANAGENE have been supplying Peptide Nucleic Acid (PNA) worldwide and exclusively since 2006 based on our unique invention of efficient synthesis of PNA with high purity, and nowadays we are possessing the best knowledge on PNA and the largest ...
Lung cancer is a metastatic cancer which the cancer cells are developed in the bronchial tubes or alveoli and grow along the blood vessel or lymphatic vessel. There are two types of lung ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in ovarian ...
based inWoodcliff Lake, NEW JERSEY (USA)
Eagle is a specialty pharmaceutical company working to advance safe and efficient injectable treatments for patients across oncology, critical care, and orphan diseases. At Eagle, we are committed to developing innovative drugs that result in ...
Indication: PEMFEXY is indicated in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). PEMFEXY is indicated as a ...
based inToronto, ONTARIO (CANADA)
Theralase was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics. With our multi-discipline experience in physics, ...
Theralase is laser focused on advancing the cutting-edge Anti-Cancer Therapy (“ACT”) towards commercialization, providing an alternative treatment methodology for Non-Muscle Invasive Bladder Cancer (“NMIBC”) patients ...
based inBoston, MASSACHUSETTS (USA)
At PathAI, we’re dedicated to improving patient outcomes with reliable AI-Powered technology and meaningful collaboration with biopharma, laboratories, and clinicians — aiming to provide patients with access to accurate diagnoses and effective ...
PathExploreTM offers unprecedented spatial and cellular resolution of the tumor microenvironment (TME) from H&E images. PathExplore is an AI-powered panel of histopathology features that spatially characterize the tumor microenvironment (TME) ...
based inCambridge, MASSACHUSETTS (USA)
Alphageneron Pharmaceuticals is a clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer cells (NK) cell and antibody-based therapies to treat cancer. Our seasoned team of biopharmaceutical executives, ...
An allogenic NK cell therapy that targets tumors expressing mHsp70. Patients are selected with high mHsp70 exosomes in their blood using our Companion Diagnostic AP-CDx (described below). We obtain PBMCs from healthy donors by apheresis, their NK ...
based inBoston, MASSACHUSETTS (USA)
SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 790 institutions in over 70 countries. Our network advances data-driven medicine to improve health outcomes and economics worldwide. We offer a ...
Unlocking the potential of precision medicine with Artificial Intelligence – enabled data-driven insights. Advance targeted therapy development by harnessing the power of data and multimodal analytics. Advances in molecular and imaging ...
based inBarcelona, SPAIN
INTERmedic is a dynamic company that is still expanding, after more than 25 years in the medical technology business sector. INTERmedic develops, manufactures and distributes innovative medical systems, based on the most advanced laser technology ...
INTERmedic, worldwide leader in photodynamic therapy for pulmonology (lung cancer), gastroenterology (Barrett’s esophagus, esophageal cancer), urology (prostate cancer) among others, presents Multidiode™ PDT, an innovative technology to ...
based inCopenhagen V, DENMARK
Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. We are led by an experienced ...
Amivantamab is a fully human bispecific antibody that targets EGFR and Met, two validated cancer targets. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. to create and develop bispecific antibodies using Genmab’s ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
based inNantes, FRANCE
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics ...
Tedopi®, OSE Immunotherapeutics’s most advanced product and therapeutic neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several ...
based inSarıyer, TURKEY
Virasoft Inc. was founded in 2015 with the support of the Turkish Ministry of Industry and Technology. We develop institution-specific projects in 4 main areas that meet all the needs of an institution in digital pathology. We focus on four main ...
Programmed cell death protein 1 (PD-1; also called CD279) is one of the co-inhibitory receptors that is expressed on the surface of antigen-stimulated T cells [1]. Normally, PD-L1 expression can be detected on hematopoietic cells including T cells, ...
based inVillejuif, FRANCE
Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, ...
Get ready-to-use, fully-validated panels for the detection and quantification of nucleic acids. Crystal Digital PCR™ kits allows researchers to detect and quantify nucleic acids with ready-to-use, pre-designed assays for fully-validated target ...
based inMalvern, PENNSYLVANIA (USA)
We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase ...
Harnessing the Anticancer Power of Hydrogen Peroxide: As cancer cells are more susceptible than normal cells to increased levels of hydrogen peroxide, we believe the conversion of radiation-generated superoxide to hydrogen peroxide by our selective ...
based inWroclaw, POLAND
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based ...
In cancer, a balance between immune system effector and regulatory cells becomes disturbed. Regulatory T cells inhibit the activity of effector cells, including NK cells, a process known as immunosuppression. The PB003 (PureActivator) project ...
based inEpalinges, SWITZERLAND
AC BioScience Ltd., a clinical-stage biotech company and a developer of immune modulating and angiogenic cancer therapies. AC BioScience LTD. is a Swiss biotech company, pioneering the development of novel therapies in immuno-oncology and tumor ...
Our product is a new-generation CAP6 that shows great promise as a highly effective treatment for lung cancer (NSCLC). Lung cancer is one of the most widely prevalent cancers, and ...
based inCarlsbad, CALIFORNIA (USA)
Our mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage’s programs are based on the Company’s proprietary cell-based therapy platform and associated ...
VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells. VAC2, which is produced from our ...
based inVienna, AUSTRIA
ViennaLab Diagnostics specializes in easy-to-use in vitro diagnostic assays for the detection of genetic variants associated with genetic disorders, genetic predispositions, pharmacogenetics, cancer, and the human microbiome. Our focus is on product ...
A reliable tool to personalize therapy of lung cancer patients with acquired TKI-resistance mutation T790M in the EGFR ...
based inBoston, MASSACHUSETTS (USA)
We harness the natural power of the lymph nodes to generate enhanced immune responses against tumors. Our science is defining the future of immunotherapy, with the goal of giving patients who are battling cancer their best possible outcome. We’re ...
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight against the most ...